

Rui Guo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7986638/publications.pdf>

Version: 2024-02-01

63
papers

2,521
citations

218592

26
h-index

223716

46
g-index

63
all docs

63
docs citations

63
times ranked

2283
citing authors

#	ARTICLE	IF	CITATIONS
1	Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2420-2425.	0.8	44
2	Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses. <i>Molecular Cancer</i> , 2021, 20, 14.	7.9	48
3	Unambiguous advanced radiologic extranodal extension determined by MRI predicts worse outcomes in nasopharyngeal carcinoma: Potential improvement for future editions of N category systems. <i>Radiotherapy and Oncology</i> , 2021, 157, 114-121.	0.3	32
4	Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. <i>Lancet</i> , The, 2021, 398, 303-313.	6.3	98
5	Epstein-Barr virus microRNA BART10-3p promotes dedifferentiation and proliferation of nasopharyngeal carcinoma by targeting ALK7. <i>Experimental Biology and Medicine</i> , 2021, 246, 2618-2629.	1.1	5
6	Nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: clinical outcomes and patterns of failure among subsets of 8th AJCC stage IVa. <i>European Radiology</i> , 2020, 30, 816-822.	2.3	23
7	New parameters of the 8th edition AJCC/UICC T category in nasopharyngeal carcinoma: Cervical vertebrae invasion and parotid gland invasion. <i>Clinical and Translational Medicine</i> , 2020, 10, e202.	1.7	1
8	Prognostic value of MRI-determined cervical lymph node size in nasopharyngeal carcinoma. <i>Cancer Medicine</i> , 2020, 9, 7100-7106.	1.3	11
9	A New Model for Predicting Hypothyroidism After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 551255.	1.3	13
10	A Nomogram Based on Serum Biomarkers and Clinical Characteristics to Predict Survival in Patients With Non-Metastatic Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 594363.	1.3	13
11	Identification of cross-talk between m6A and 5mC regulators associated with onco-immunogenic features and prognosis across 33 cancer types. <i>Journal of Hematology and Oncology</i> , 2020, 13, 22.	6.9	47
12	Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis. <i>Oral Oncology</i> , 2020, 105, 104686.	0.8	14
13	The evolution of nasopharyngeal carcinoma staging. <i>British Journal of Radiology</i> , 2019, 92, 20190244.	1.0	73
14	Thyroid dose-volume thresholds for the risk of radiation-related hypothyroidism in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: A single-institution study. <i>Cancer Medicine</i> , 2019, 8, 6887-6893.	1.3	19
15	Lymph Node Status and Outcomes for Nasopharyngeal Carcinoma According to Histological Subtypes: A SEER Population-Based Retrospective Analysis. <i>Advances in Therapy</i> , 2019, 36, 3123-3133.	1.3	18
16	Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. <i>New England Journal of Medicine</i> , 2019, 381, 1124-1135.	13.9	573
17	Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 355-361.	0.4	64
18	Patterns of EBV-positive cervical lymph node involvement in head and neck cancer and implications for the management of nasopharyngeal carcinoma T0 classification. <i>Oral Oncology</i> , 2019, 91, 7-12.	0.8	16

#	ARTICLE	IF	CITATIONS
19	Hypermethylation of <i>SHISA3</i> Promotes Nasopharyngeal Carcinoma Metastasis by Reducing SCSM1 Stability. <i>Cancer Research</i> , 2019, 79, 747-759.	0.4	35
20	Optimizing the cumulative cisplatin dose during radiotherapy in nasopharyngeal carcinoma: Dose-effect analysis for a large cohort. <i>Oral Oncology</i> , 2019, 89, 102-106.	0.8	16
21	Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. <i>Cancer</i> , 2019, 125, 79-89.	2.0	143
22	Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis. <i>Oral Oncology</i> , 2018, 78, 37-45.	0.8	20
23	Surgical treatment indications and outcomes in patients with spinal metastases in the cervicothoracic junction (CTJ). <i>Journal of Orthopaedic Surgery and Research</i> , 2018, 13, 20.	0.9	8
24	Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area. <i>Cancer Research and Treatment</i> , 2018, 50, 777-790.	1.3	8
25	Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy. <i>Oral Oncology</i> , 2017, 69, 99-107.	0.8	48
26	Socioeconomic factors and survival in patients with non-metastatic head and neck squamous cell carcinoma. <i>Cancer Science</i> , 2017, 108, 1253-1262.	1.7	33
27	Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2017, 123, 1643-1652.	2.0	48
28	Use of pretreatment serum uric acid level to predict metastasis in locally advanced nasopharyngeal carcinoma. <i>Head and Neck</i> , 2017, 39, 492-497.	0.9	8
29	Impact of marital status at diagnosis on survival and its change over time between 1973 and 2012 in patients with nasopharyngeal carcinoma: a propensity score-matched analysis. <i>Cancer Medicine</i> , 2017, 6, 3040-3051.	1.3	26
30	Delayed clinical complete response to intensity-modulated radiotherapy in nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2017, 75, 120-126.	0.8	12
31	Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with NO-category nasopharyngeal carcinoma and enlarged neck lymph nodes. <i>Chinese Journal of Cancer</i> , 2017, 36, 32.	4.9	9
32	Changes in Disease Failure Risk of Nasopharyngeal Carcinoma over Time: Analysis of 749 Patients with Long-Term Follow-Up. <i>Journal of Cancer</i> , 2017, 8, 455-459.	1.2	36
33	Significant value of 18F-FDG-PET/CT in diagnosing small cervical lymph node metastases in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. <i>Chinese Journal of Cancer</i> , 2017, 36, 95.	4.9	25
34	Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy. <i>Chinese Journal of Cancer</i> , 2017, 36, 87.	4.9	53
35	Implication of comorbidity on the initiation of chemotherapy and survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Oncotarget</i> , 2017, 8, 10594-10601.	0.8	5
36	Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status. <i>Oncotarget</i> , 2016, 7, 24208-24216.	0.8	43

#	ARTICLE	IF	CITATIONS
37	Should All Nasopharyngeal Carcinoma with Paranasal Sinus Invasion Be Staged as T3 in the Intensity-Modulated Radiotherapy Era? A Study of 1811 Cases. <i>Journal of Cancer</i> , 2016, 7, 1353-1359.	1.2	12
38	Prognostic Value of Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma with Low Pre-treatment Epstein-Barr Virus DNA: a Propensity-matched Analysis. <i>Journal of Cancer</i> , 2016, 7, 1465-1471.	1.2	14
39	Circulating EBV DNA, Globulin and Nodal Size Predict Distant Metastasis after Intensity-Modulated Radiotherapy in Stage II Nasopharyngeal Carcinoma. <i>Journal of Cancer</i> , 2016, 7, 664-670.	1.2	27
40	Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy. <i>Scientific Reports</i> , 2016, 6, 22000.	1.6	58
41	Prognostic Value of the Cumulative Cisplatin Dose During Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Secondary Analysis of a Prospective Phase III Clinical Trial. <i>Oncologist</i> , 2016, 21, 1369-1376.	1.9	50
42	Prognostic value of Diabetes in Patients with Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy. <i>Scientific Reports</i> , 2016, 6, 22200.	1.6	7
43	The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy. <i>Scientific Reports</i> , 2016, 6, 24332.	1.6	22
44	The Tumour Response to Induction Chemotherapy has Prognostic Value for Long-Term Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma. <i>Scientific Reports</i> , 2016, 6, 24835.	1.6	52
45	Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma. <i>Oncotarget</i> , 2016, 7, 9576-9585.	0.8	19
46	Cigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study. <i>Oncotarget</i> , 2016, 7, 16806-16817.	0.8	9
47	Primary tumor inflammation in gross tumor volume as a prognostic factor for nasopharyngeal carcinoma patients. <i>Oncotarget</i> , 2016, 7, 14963-14972.	0.8	4
48	Prognostic value of wait time in nasopharyngeal carcinoma treated with intensity modulated radiotherapy: a propensitymatched analysis. <i>Oncotarget</i> , 2016, 7, 14973-14982.	0.8	21
49	The efficacy and toxicity of individualized intensity-modulated radiotherapy based on the tumor extension patterns of nasopharyngeal carcinoma. <i>Oncotarget</i> , 2016, 7, 20680-20690.	0.8	15
50	Neoadjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: Defining high-risk patients who may benefit before concurrent chemotherapy combined with intensity-modulated radiotherapy. <i>Scientific Reports</i> , 2015, 5, 16664.	1.6	34
51	Prognostic value of parotid lymph node metastasis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy. <i>Scientific Reports</i> , 2015, 5, 13919.	1.6	10
52	Efficacy of Concurrent Chemotherapy for Intermediate Risk NPC in the Intensity-Modulated Radiotherapy Era: a Propensity-Matched Analysis. <i>Scientific Reports</i> , 2015, 5, 17378.	1.6	23
53	Investigation of the feasibility of elective irradiation to neck level Ib using intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma: a retrospective analysis. <i>BMC Cancer</i> , 2015, 15, 709.	1.1	29
54	Value of the prognostic nutritional index and weight loss in predicting metastasis and long-term mortality in nasopharyngeal carcinoma. <i>Journal of Translational Medicine</i> , 2015, 13, 364.	1.8	67

#	ARTICLE	IF	CITATIONS
55	Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy. <i>BMC Cancer</i> , 2015, 15, 810.	1.1	24
56	Dosimetric benefit to organs at risk following margin reductions in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. <i>Chinese Journal of Cancer</i> , 2015, 34, 189-97.	4.9	12
57	Clinical Outcomes of Volume-Modulated Arc Therapy in 205 Patients with Nasopharyngeal Carcinoma: An Analysis of Survival and Treatment Toxicities. <i>PLoS ONE</i> , 2015, 10, e0129679.	1.1	20
58	Efficacy of the Additional Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Bayesian Network Meta-analysis of Randomized Controlled Trials. <i>Journal of Cancer</i> , 2015, 6, 883-892.	1.2	68
59	Comorbidity predicts poor prognosis in nasopharyngeal carcinoma: Development and validation of a predictive score model. <i>Radiotherapy and Oncology</i> , 2015, 114, 249-256.	0.3	21
60	Identification of miR-143 as a tumour suppressor in nasopharyngeal carcinoma based on microRNA expression profiling. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 61, 120-128.	1.2	30
61	Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials. <i>Radiotherapy and Oncology</i> , 2015, 116, 157-166.	0.3	24
62	Prognostic Value and Staging Classification of Retropharyngeal Lymph Node Metastasis in Nasopharyngeal Carcinoma Patients Treated with Intensity-modulated Radiotherapy. <i>PLoS ONE</i> , 2014, 9, e108375.	1.1	35
63	Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 110, 390-397.	0.3	126